Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2024-02-07 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
关于2024年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the expected daily related-party transactions for the year 2024. It details the nature, amounts, and pricing policies of these related-party transactions, including sales, services, and financial services with related entities. The document includes board and independent director approvals, compliance with regulatory rules, and a sponsor's verification opinion. It is a formal disclosure about related-party transactions, not a full financial report or audit. It does not contain comprehensive financial statements or quarterly results, nor is it a voting result or management change announcement. The content fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about related-party transactions without constituting a full report like an Annual Report or Interim Report.
2024-02-07 Chinese
关于公司产品美沙拉秦肠溶缓释片获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product registration certificate by the National Medical Products Administration (国家药品监督管理局). It details the product name, registration classification, approval number, and the impact on the company. There is no financial data, no mention of financial results, no regulatory filings related to financial reporting, and no indication of a report or meeting materials. The document is an official announcement about a regulatory approval related to product registration, which fits best under general regulatory announcements that do not fit other specific categories. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is short and it is not a report publication announcement or certification letter, so RNS is the best fit.
2024-02-04 Chinese
关于变更签字注册会计师的公告
Audit Report / Information Classification · 95% confidence The document is an announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding a change in the signing certified public accountant for the company's 2023 audit. It references the appointment of the audit firm for the 2023 fiscal year and details the replacement of one signing CPA with another. The document does not contain any financial statements or audit results itself, but rather informs about a personnel change related to the audit process. It is short (1078 characters) and serves as a formal notification about the change in auditors. Therefore, it fits the category of Audit Report / Information (AR), which includes standalone audit reports and related announcements about audit personnel changes, excluding full annual reports. FY 2023
2024-01-12 Chinese
关于自愿披露公司产品新纳入国家医保目录的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure that one of its products has been newly included in the national medical insurance catalog. It contains no financial statements, no management discussion of financial results, no voting results, no regulatory certifications, or other report types. It is a regulatory announcement about product inclusion in a government insurance list, which affects the company's business outlook but is not a financial report or meeting material. The document length is short (796 characters), and it is a standalone announcement. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-12-14 Chinese
关于自愿披露公司产品中选国家组织药品集中带量采购的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of a product winning a national centralized drug procurement bid. It details the product, pricing, supply provinces, and potential impact on the company. There is no financial report, earnings data, or regulatory certification. The document is an announcement about a procurement result and its business impact, not a financial report or regulatory filing. It fits best under a general regulatory announcement category rather than a specific financial report or meeting material. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is short and it is not a report publication announcement or certification.
2023-11-17 Chinese
关于召开2023年第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2023 third quarter earnings explanation meeting (业绩说明会) to be held on November 28, 2023. It references that the company has already released its 2023 third quarter report on October 31, 2023, and the meeting is intended to provide further explanation and answer investor questions. The document does not contain actual financial data or the report itself, but rather details about the upcoming investor call. The document length is short (1476 characters) and it is clearly an announcement of a meeting rather than the meeting transcript or the financial report. Therefore, it fits best into the category of Call Transcript (CT) announcement or Investor Presentation (IP) announcement. However, since it is specifically about an earnings explanation meeting (业绩说明会), which is a form of investor presentation focused on financial results and Q&A, the best classification is Investor Presentation (IP).
2023-11-15 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.